Skip to main content

Advertisement

SpringerLink
Log in

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objective of the study was to determine the presence or levels of antibodies (Abs) against caspase-3 and their clinical relevance in systemic sclerosis (SSc). Anti-caspase-3 Ab was examined by enzyme-linked immunosorbent assay and immunoblotting. IgG anti-caspase-3 Ab levels in SSc patients were higher than in normal controls. SSc patients positive for IgG anti-caspase-3 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-caspase-3 Ab levels correlated positively with serum IgG levels, renal vascular resistance, and serum levels of 8-isoprostane. Immunoblotting analysis confirmed the presence of anti-caspase-3 Ab in sera from SSc patients. Caspase-3 enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-caspase-3 Ab. These results suggest that autoantibody against caspase-3 is generated in SSc and that this Ab is related to the severity of pulmonary fibrosis, vascular damage, and inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Okano Y (1996) Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 22:709–735

    Article  CAS  PubMed  Google Scholar 

  2. Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93

    CAS  PubMed  Google Scholar 

  3. Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593

    Article  CAS  PubMed  Google Scholar 

  4. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H (2008) Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 158:19–28

    Article  PubMed  Google Scholar 

  5. Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K et al (2007) Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology 46:790–795

    Article  CAS  PubMed  Google Scholar 

  6. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K et al (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357–363

    Article  CAS  PubMed  Google Scholar 

  7. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120:542–547

    Article  CAS  PubMed  Google Scholar 

  8. Matucci Cerinic M, Kahaleh MB (2002) Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 41:843–847

    Article  CAS  PubMed  Google Scholar 

  9. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562

    Article  CAS  PubMed  Google Scholar 

  10. Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15:725–731

    Article  CAS  PubMed  Google Scholar 

  11. Nadiri A, Wolinski MK, Saleh M (2006) The inflammatory caspases: key players in the host response to pathogenic invasion and sepsis. J Immunol 177:4239–4245

    CAS  PubMed  Google Scholar 

  12. Fang B, Boross PI, Tozser J, Weber IT (2006) Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. J Mol Biol 360:654–666

    Article  CAS  PubMed  Google Scholar 

  13. Ni CZ, Li C, Wu JC, Spada AP, Ely KR (2003) Conformational restrictions in the active site of unliganded human caspase-3. J Mol Recognit 16:121–124

    Article  CAS  PubMed  Google Scholar 

  14. Sisto M, Lisi S, Castellana D, Scagliusi P, D’Amore M, Caprio S et al (2006) Autoantibodies from Sjogren’s syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 27:38–49

    Article  CAS  PubMed  Google Scholar 

  15. Yamamoto T, Nishioka K (2004) Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 122:44–50

    Article  CAS  PubMed  Google Scholar 

  16. Elizabeth AS, Colon A, Seamus JM (2001) Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326

    Article  Google Scholar 

  17. Sabbagh L, Kaech SM, Bourbonniere M, Woo M, Cohen LY, Haddad EK et al (2004) The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 173:5425–5433

    CAS  PubMed  Google Scholar 

  18. Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F (2006) Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol 239:121–128

    Article  CAS  PubMed  Google Scholar 

  19. Cipriani P, Fulminis A, Pingiotti E, Marrelli A, Liakouli V, Perricone R et al (2006) Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. J Rheumatol 33:2003–2014

    CAS  PubMed  Google Scholar 

  20. Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M et al (2002) Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 129:556–561

    Article  CAS  PubMed  Google Scholar 

  21. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590

  22. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205

    CAS  PubMed  Google Scholar 

  23. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896

    CAS  PubMed  Google Scholar 

  24. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391–394

    Article  CAS  PubMed  Google Scholar 

  25. Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K et al (2001) Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 40:109–406

    Article  Google Scholar 

  26. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643

    CAS  PubMed  Google Scholar 

  27. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K et al (2006) Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 45:815–818

    Article  CAS  PubMed  Google Scholar 

  28. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K et al (1993) Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 36:1137–1141

    Article  CAS  PubMed  Google Scholar 

  29. Morrow JD, Roberts LJ 2nd (1996) The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51:1–9

    Article  CAS  PubMed  Google Scholar 

  30. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792

    Article  CAS  PubMed  Google Scholar 

  31. Casiano CA, Martin SJ, Green DR, Tan EM (1996) Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 184:765–770

    Article  CAS  PubMed  Google Scholar 

  32. Panchenko MV, Farber HW, Korn JH (2000) Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 278:C92–C101

    CAS  PubMed  Google Scholar 

  33. Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32:679–686

    CAS  PubMed  Google Scholar 

  34. Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist’s perspective. Trends Pharmacol Sci 16:18–22

    Article  CAS  PubMed  Google Scholar 

  35. Dosreis GA, Borges VM, Zin WA (2004) The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 8:285–293

    Article  CAS  PubMed  Google Scholar 

  36. Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M et al (2002) TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 168:6470–6478

    CAS  PubMed  Google Scholar 

  37. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, Bouros D (2005) Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127:266–274

    Article  PubMed  Google Scholar 

  38. Nagy G, Koncz A, Perl A (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25:123–140

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant of Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan.

Author information

Authors and Affiliations

  1. Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan

    Shihoko Okazaki, Fumihide Ogawa, Yohei Iwata, Toshihide Hara, Eiji Muroi, Kazuhiro Komura, Motoi Takenaka, Kazuhiro Shimizu & Shinichi Sato

  2. Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

    Minoru Hasegawa & Manabu Fujimoto

Authors
  1. Shihoko Okazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumihide Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yohei Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihide Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiji Muroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Komura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Motoi Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Minoru Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Manabu Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinichi Sato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okazaki, S., Ogawa, F., Iwata, Y. et al. Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. Rheumatol Int 30, 871–878 (2010). https://doi.org/10.1007/s00296-009-1068-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1068-3

Keywords

Search

Navigation